Does glyceryl nitrate prevent post-ERCP pancreatitis? A prospective, randomized, double-blind, placebo-controlled...

Area of Science:

• Gastroenterology
• Clinical Trials
• Pharmacology

Background:

• Post-ERCP pancreatitis (PEP) is a significant complication of endoscopic retrograde cholangiopancreatography (ERCP).
• Previous studies suggested glyceryl nitrate (GN) may reduce PEP incidence.

Purpose of the Study:

• To evaluate the efficacy of transdermal glyceryl nitrate (GN) in preventing post-ERCP pancreatitis (PEP).
• To assess GN's effect in a large, multicenter, randomized controlled trial.

Main Methods:

• A randomized, double-blind, placebo-controlled multicenter study.
• 806 patients undergoing ERCP were randomized to receive either transdermal GN (15 mg/24 hours) or placebo.
• PEP incidence and severity were assessed.

Main Results:

• PEP occurred in 4.5% of the GN group and 7.1% of the placebo group (relative risk reduction of 36%, P = .11).
• The reduction in PEP incidence with GN was not statistically significant.
• Headache and hypotension were more frequent adverse events in the GN group.

Conclusions:

• Transdermal glyceryl nitrate did not demonstrate a statistically significant preventive effect on PEP in this study.
• A potential benefit of GN may have been missed due to the risk of a type II error.
• Further research may be needed to clarify GN's role in PEP prevention.